Literature DB >> 9582336

Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia.

L Legeai-Mallet1, C Benoist-Lasselin, A L Delezoide, A Munnich, J Bonaventure.   

Abstract

Thanatophoric dysplasia (TD) is a lethal skeletal disorder caused by recurrent mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene. The mitogenic response of fetal TD I chondrocytes in primary cultures upon stimulation by either FGF 2 or FGF 9 did not significantly differ from controls. Although the levels of FGFR 3 mRNAs in cultured TD chondrocytes were similar to controls, an abundant immunoreactive material was observed at the perinuclear level using an anti-FGFR 3 antibody in TD cells. Transduction signaling via the mitogen-activated protein kinase pathway was assessed by measuring extracellular signal-regulated kinase activity (ERK 1 and ERK 2). Early ERKs activation following FGF 9 supplementation was observed in TD chondrocytes (2 min) as compared with controls (5 min) but no signal was detected in the absence of ligand. By contrast ligand-independent activation of the STAT signaling pathway was demonstrated in cultured TD cells and confirmed by immunodetection of Stat 1 in the nuclei of hypertrophic TD chondrocytes. Moreover, the presence of an increased number of apoptotic chondrocytes in TD fetuses was associated with a higher expression of Bax and the simultaneous decrease of Bcl-2 levels. Taken together, these results indicate that FGFR 3 mutations in TD I fetuses do not hamper chondrocyte proliferation but rather alter their differentiation by triggering premature apoptosis through activation of the STAT signaling pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582336     DOI: 10.1074/jbc.273.21.13007

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

2.  Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

Authors:  S Murakami; M Kan; W L McKeehan; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 4.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

5.  FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence.

Authors:  Pavel Krejci; Jirina Prochazkova; Jiri Smutny; Katarina Chlebova; Patricia Lin; Anie Aklian; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Bone       Date:  2010-03-31       Impact factor: 4.398

Review 6.  FGF signaling in the developing endochondral skeleton.

Authors:  David M Ornitz
Journal:  Cytokine Growth Factor Rev       Date:  2005-04-01       Impact factor: 7.638

7.  Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Petra Jelinkova; Katerina Pejchalova; Alois Kozubik; Leslie Michels Thompson; William R Wilcox
Journal:  Cell Signal       Date:  2008-10-12       Impact factor: 4.315

8.  Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Authors:  Davide Komla-Ebri; Emilie Dambroise; Ina Kramer; Catherine Benoist-Lasselin; Nabil Kaci; Cindy Le Gall; Ludovic Martin; Patricia Busca; Florent Barbault; Diana Graus-Porta; Arnold Munnich; Michaela Kneissel; Federico Di Rocco; Martin Biosse-Duplan; Laurence Legeai-Mallet
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

9.  Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.

Authors:  Sarah Cormier; Anne-Lise Delezoide; Catherine Benoist-Lasselin; Laurence Legeai-Mallet; Jacky Bonaventure; Caroline Silve
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

10.  New insight on FGFR3-related chondrodysplasias molecular physiopathology revealed by human chondrocyte gene expression profiling.

Authors:  Laurent Schibler; Linda Gibbs; Catherine Benoist-Lasselin; Charles Decraene; Jelena Martinovic; Philippe Loget; Anne-Lise Delezoide; Marie Gonzales; Arnold Munnich; Jean-Philippe Jais; Laurence Legeai-Mallet
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.